Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 162

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 162
---
 achieved sales of € 151 million in 2024 (+ 68.1% CER), with most of the growth coming in the United States. Enjaymo (cold agglutinin disease) posted sales of € 105 million, up 48.6% CER , driven by all regions. On November 29, 2024, Sanofi entered into a definitive agreement with Recordati for the sale of its worldwide rights to Enjaymo. Sales of Tzield (delayed onset of type 1 diabetes) amounted to € 54 million. As expected, sales are on a gradual uptrend, driven by continued growth in infusions supported by increased awareness and screening. Immunology & Inflammation Dupixent (collaboration with Regeneron) generated net sales of € 13,072 million in 2024 , up 22.0 % on a reported basis and 23.1% at constant exchange rates. In the United States, sales of Dupixent reached € 9,544 million (+ 17.2 % CER), driven by continuing strong demand in the product’s approved indications: atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis, and prurigo nodularis. In Europe, the product’s net sales for 2024 totaled € 1,618 million, up 31.9 % CER, reflecting continued growth in all approved indications and emerging sales in chronic obstructive pulmonary disease (COPD). In the Rest of the World region, Dupixent posted net sales of € 1,910 million ( +50.8 % CER), driven mainly by Japan and China. More than one million patients are currently being treated with Dupixent globally. Other medicines Lantus sales increased to € 1,628 million (+ 20.8% CER) . In the United States, sales were up 127.0% CER, reflecting the withdrawal of a competing medicine from the market and a lower comparative base in terms of net-price adjustments. In the Rest of the World region and Europe, sales were down by 5.8% and 4.8% CER, respectively, mainly due to the strategy of switching to Toujeo in China . Toujeo sales increased by 13.4% CER to € 1,227 million, driven by China, where the product’s